Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TGF-beta activated kinase 1 binding protein 2 (TAB2)
- Target
- TAB2
- Molecular classification
- Adapter protein, Signal transduction protein, Scaffold protein
01
Overview
TGF-beta activated kinase 1 binding protein 2 (TAB2) is a signal transduction adapter protein essential for the activation of the MAPK/JNK and NF-kappaB pathways in response to interleukin-1 and other pro-inflammatory stimuli[1][7]. It interacts with polyubiquitin chains (Lys63-linked) and forms functional complexes with kinases like MAP3K7 (TAK1) and TRAF6, linking these components in key signaling cascades involved in inflammation, immunity, and development[1][5]. TAB2 is critical for heart development, and mutations can cause congenital heart defects and related syndromes[7][1]. While not a direct target of any approved drugs, it plays a central scaffolding role in cytokine and stress response pathways that are therapeutically targeted in inflammatory and oncologic diseases[1][4][7].
- Other names
- MAP3K7IP2TGF-beta-activated kinase 1 and MAP3K7-binding protein 2TAB2_HUMANTGF-beta activated kinase 1 (MAP3K7) binding protein 2
02
Mechanism of action
Drugs targeting upstream or downstream kinases in the MAPK or NF-kappaB pathways may modulate TAB2-mediated signaling, typically by inhibiting kinase activity or blocking downstream inflammatory responses[1][7].
03
Biological functions
Signal transductionActivation of JNK and NF-kappaB pathwaysMediating Toll-like receptor pathwaysCellular response to inflammatory cytokinesHeart developmentOsteoclast differentiation
04
Disease associations
Congenital heart defectsCardiac anomalies-short stature-joint hypermobility-facial dysmorphism syndromeInflammationPotential cancer-related signaling via NF-kappaB and MAPK pathways
05
Safety considerations
Targeting TAB2 directly may risk widespread immune modulation or cardiovascular defects given its role in fundamental inflammatory and developmental signaling[1][2].Mutations lead to congenital heart defects, indicating developmental liabilities if pathway is perturbed in early life[1][7].
06
Interacting drugs
No direct drug interactions are well characterized for TAB2 as a primary drug target; it acts as an adaptor in pathways targeted by certain anti-inflammatory and anti-cancer agents, but is not the direct molecular target of approved drugs[1][7].
07
Biomarkers
Mutations in TAB2 serve as biomarkers for congenital heart defects and related syndromes[7][1].Altered TAB2 signaling or protein levels can be associated with inflammatory and cardiac diseases[2].
Beyond the preview
Go deeper on TGF-beta activated kinase 1 binding protein 2 (TAB2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGF-beta activated kinase 1 binding protein 2 (TAB2).